Skip to main content

Table 2 Progression free survival for patients treated with doxorubicin and olaratumab in our study

From: Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

GroupMedian PFS95% CI
All patients6.85.9–7.7
Liposarcoma9.66.1–13.1
UPS5.73.8–7.6
Leiomyosarcoma6.25.2–7.2